Modern Experience of Pharmacotherapeutic Use and Effectiveness of Endolumbal Administration of Glucocorticoids in Progressive Types of Course for Multiple Sclerosis
DOI:
https://doi.org/10.53933/sspmpm.v4i3.157Keywords:
multiple sclerosis, progressive courses, intrathecal introduction of glucocorticoids, efficiencyAbstract
Effective pharmacotherapy of low-bondly progredient forms of the multiple sclerosis is a difficult task that requires the search for new and improving existing methods of treatment. The author set the task to the optimize the treatment of progredient forms of multiple sclerosis using the method of endolumbal introduction of glucocorticoids and to evaluate its efficiency. The results of treatment of 76 patients with poor curable progresses of multiple sclerosis by intratracal introduction of glucocorticoids (dexamethasone) are presented in the study. The advantages of method, methodic of introduction, the patient`s selection parameters were given. The efficiency criterions of intration of glucocorticoids were defined, including the neurological deficiency regress, stabilization and the delay of multiple sclerosis progressing. Integral assessment of efficiency was made as 4 gradations: “good rate”, “low” and “absence of effect”. The positive dynamics of neurological state was registered predominantly on spastic-paretic syndrome with presence of several active foci with contrast enhancement. The sphincter infringements and brain stem symptomatic were observed as rarely reversible, extremely rarely - cerebellar symptom complex. As the results of the treatment (the term of the observation – 6 months and more) 80.2% of multiple sclerosis patrols marked the efficiency as "good" and "moderate". The obtained data indicated the reasonability of the proposed method of treatment for patrols with saversive counses of multiple sclerosis, occurring inly with spinal symptomatic.
References
Multiple sclerosis. WHO. 7.08.2023. URL: https://www.who.int/news-room/fact-sheets/detail/multiple-sclerosis.
Shapovalova V.A., Voloshyn P.V., Stefanov A.V. et al. Medicines for neurologists, psychiatrists and narcologists. Kh.: «Fakt». 2003. 784 p.
Voloshin PV Mental health protection of all segments of the population of Ukraine: modern medical-pharmaceutical, socio-economic and psychological and pedagogical opportunities on the principles of medical and pharmaceutical law. Materials of the XII Scientific and Practical Conference with the participation of international specialists "Slobozhansky readings. Pharmaceutical and medical law of Ukraine: innovations, quality, safety and prospects for the development of pharmaceutical self -government". Ukrainian Bulletin of Psychoneurology. 2015. T. 23. Iss. 3 (84). Addition. P. 156. URL: https://uvnpn.com.ua/upload/iblock/d9d/d9d1c6866e7f61f439f3148726be3dde.pdf.
Shapovalova V. The ICD-11 for the twenty-first century: the first view from the organizational, legal, clinical and pharmacological aspects. SSP Modern Pharmacy and Medicine. 2022. Vol.2. N.1. P.1-13. URL: https://doi.org/10.53933/sspmpm.v2i1.37 DOI: https://doi.org/10.53933/sspmpm.v2i1.37
Jiwon Oh. A Medical Preview of 2024 for Multiple Sclerosis and Related Disorders: Jiwon Oh, MD, PhD. NeurologyLive. 11.02.2024. URL: https://www.neurologylive.com/view/medical-preview-2024-ms-related-disorders-jiwon-oh.
Cree B.A.C., Oksenberg J.R., Hauser S.L. Multiple sclerosis: two decades of progress. Lancet Neurol. 2022. Vol. 21. No. 3. P. 211-214. doi: 10.1016/S1474-4422(22)00040-0/. URL: https://pubmed.ncbi.nlm.nih.gov/35182500/ DOI: https://doi.org/10.1016/S1474-4422(22)00040-0
Hauser S.L. Progress in Multiple Sclerosis Research: An Example of Bedside to Bench. JAMA. 2020. Vol. 324. No. 9. Р. 841-842. DOI: 10.1001/jama.2020.1522. URL: https://jamanetwork.com/journals/jama/article-abstract/2765943 DOI: https://doi.org/10.1001/jama.2020.1522
Health of Ukraine: the thematic number "Neurology, psychiatry, psychotherapy". 2020. No. 2(53). 55 p. URL: https://health-ua.com/newspaper/tn_nevro_psiholigiya_psihoteraoiya/50274-tematichnij-nomer-nevrologya-psihatrya-psihoterapya--2--53-2020-r.
Gusev E.I., Zavalishin I.A., Noiko A.N. Multiple sclerosis and other demyelinating diseases. M.: Miklosh. 2004. 540 p.
Voloshyn P.V., Voloshyna N.P., Taitslin V.I. et al. Current aspects of multiple sclerosis: pathogenesis, peculiarities of disease course in Ukraine, diagnosis, standards of pathogenetic therapy. Neuron-Review (Journal of Clinical Neurosciences). 2007. No. 3. P. 4-26.
Dobson R., Giovannoni G. Multiple sclerosis – a review. Еuropean Journal of Neurology. 2018. Vol. 26. No.1. P.27-40. DOI: https://doi.org/10.1111/ene.13819. DOI: https://doi.org/10.1111/ene.13819
Negrich T.I., Voloshyna N.P., Muratova T.M. et al. Multiple sclerosis in Ukraine: personalized treatment strategy. Health of Ukraine: the thematic number "Neurology, psychiatry, psychotherapy". 2020. No. 2 (53). P. 13- URL: https://health-ua.com/multimedia/5/0/0/2/7/4/1593093235.pdf.
Nehreba TV Flowing and forecast of contemporary forms of rassean sclerosis. Certificate of copyright registration for work No. 30251 of September 15, 2009.
Voloshyna N.P., Vasylovsky V.V., Chernenko M.E. The use of the drug Mitoxantron in the treatment of patients with progressive type of multiple sclerosis. Ukr. Visn. Psychoneurol. 2005. Vol. 13. Iss. 3 (44). P. 53-55.
Voloshyna N.P., Vasylovsky V.V., Chernenko M.E. Treatment of patients with multiple sclerosis with a progressive course of endolumbal administration of glucocorticoids. Declaration Patent of Ukraine No. 68758A17ka61135/00 No. 200310 9479. Inform. Bul. AUNU "Journal of the Academy of Medical Sciences". K. 2006. Iss. 21.
Vasylovskyy V., Nehreb, T., Voloshyna N. et al. Application of Glucocorticoids in Therapy of Multiple Sclerosis. SSP Modern Pharmacy and Medicine. 2024. Vol.4. No.2. Р.1-14. DOI: https://doi.org/10.53933/sspmpm.v4i2.141. DOI: https://doi.org/10.53933/sspmpm.v4i2.141
Sharrack B., Hughes R. A.C., Morris R. W. et al. The effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in multiple sclerosis. J. Neurol. Sci. 2000. Vol. 173. P. 73-77. URL: https://pubmed.ncbi.nlm.nih.gov/10675582/. DOI: https://doi.org/10.1016/S0022-510X(99)00304-4
Tarianyk K.A., Shkodina A.D., Lytvynenko N.V. et al. Combined therapy of relapsingremitting multiple sclerosis exacerbations with plasmapheresis and glucocorticoids with regard to patients’ quality of life. Ukrainian Neurological Journal. 2020. No. 3. P. 29-34. DOI: https://doi.org/10.30978/UNJ2020-3-29. DOI: https://doi.org/10.30978/UNJ2020-3-29
Cazzato G., Mesianno., Antonello R. et al. Double-blind, placebocontrolled, randomized, crossover trial of high-dose methylprednisolone in patients with chronic progressive form of multiple sclerosis. Eur. Neurol. 1995. Vol. 35. P. 193-198. URL: https://pubmed.ncbi.nlm.nih.gov/7671978/ DOI: https://doi.org/10.1159/000117127
Voloshyna N.P., Nehreba T.V., Vasylovskyy V.V. et al. Development of prognosis dependingon the development of the progression stage and progression options in progressive types of multiple sclerosis. Ukrainian Bulletin of Psychoneurology. 2021. Vol.29. Iss.3(108). P.18-22. URL: https://uvnpn.com.ua/en/archive-of-numbers/2021/volume-29-issue-3-108/formation-of-the-forecast-character-depending-on-the-ways-of-development-of-the-progression-stage-an DOI: https://doi.org/10.36927/2079-0325-V29-is3-2021-3
Saliq S.A., Simon E.V., Puccio L.M. Intrathecal methotrexate treatment in multiple sclerosis. J. Neurol. 2010. Vol.257. P.1806-1811. URL: https://pubmed.ncbi.nlm.nih.gov/20532907/. DOI: https://doi.org/10.1007/s00415-010-5614-4
Voloshyna N., Vasylovskyy V., Nehreba T. et al. Clinical-mathematical analysis of interrelations between a character of the prognosis and peculiarities of onsets in different types of multiple sclerosis course. Georgian medical news. 2021. No. 9(318). P.132-138. URL: https://pubmed.ncbi.nlm.nih.gov/34628394//.
Voloshyna N.P., Vasylovskyy V.V., Kirzhner V.M. et al. Correlation analysis between clinical parameters in different types of multiple sclerosis. Ukrainian Bulletin of Psychoneurology. 2022. Vol. 30. Iss. 1 (110). P. 21-27. DOI: https://doi.org/10.36927/2079-0325-V30-is3-2022-94. DOI: https://doi.org/10.36927/2079-0325-V30-is1-2022-3
Nehreba T.V. Copyright for a scientific work No. 39160 dated 14.07.2011. Prognostic criteria for different types of multiple sclerosis.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Vitaliy Vasylovskyy, Tetiana Nehreba, Maksym Chernenko, Nataliya Voloshyna, Tetiana Pohulaieva, Ivan Voloshyn-Haponov
This work is licensed under a Creative Commons Attribution 4.0 International License.
